Description
Molnupiravir, an Oral Antiviral Treatment for COVID-19 | |||||||||||||||||||
200 Mg Molcovir -molnupiravir 200mg | |||||||||||||||||||
| |||||||||||||||||||
PRE ORDER ONLY DELIVERY EXPECTED DEC 2021 | |||||||||||||||||||
Molnupiravir is the world’s first oral pill to treat symptomatic COVID-19 which was approved by the UK’s Medicines and Healthcare products Regulatory Agency on 4 November 2021. Molnupiravir is originally developed by the US based pharma major Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics. |
Additional Information
200 Mg Molcovir -molnupiravir 200mg